FY2025 Earnings Forecast for Pfizer Issued By Zacks Research

Pfizer Inc. (NYSE:PFE) – Research analysts at Zacks Research cut their FY2025 EPS estimates for Pfizer in a note issued to investors on Monday, October 21st. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will earn $2.79 per share for the year, down from their prior forecast of $2.81. The consensus estimate for Pfizer’s current full-year earnings is $2.66 per share. Zacks Research also issued estimates for Pfizer’s Q1 2026 earnings at $0.71 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.79 EPS and FY2026 earnings at $2.96 EPS.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.67 earnings per share.

Several other equities research analysts have also recently issued reports on PFE. Barclays raised their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday. Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Trading Up 0.1 %

NYSE:PFE opened at $28.86 on Tuesday. The company’s 50 day moving average price is $29.07 and its 200-day moving average price is $28.48. Pfizer has a 52 week low of $25.20 and a 52 week high of $31.54. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The stock has a market cap of $163.54 billion, a price-to-earnings ratio of -481.00, a PEG ratio of 1.02 and a beta of 0.67.

Institutional Investors Weigh In On Pfizer

Several large investors have recently bought and sold shares of PFE. Olistico Wealth LLC purchased a new position in Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer during the second quarter worth $29,000. Quarry LP purchased a new position in Pfizer during the second quarter worth $31,000. Trivant Custom Portfolio Group LLC boosted its stake in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the period. Finally, Financial Connections Group Inc. purchased a new position in Pfizer during the second quarter worth $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.82%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is presently -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.